Christian Lienhardt

Summary

Affiliation: World Health Organization
Country: Switzerland

Publications

  1. ncbi New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes
    Christian Lienhardt
    Stop TB Department and Stop TB Partnership, World Health Organization, Geneva, Switzerland
    Curr Opin Pulm Med 16:186-93. 2010
  2. ncbi Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial
    Christian Lienhardt
    Clinical Trial Division, International Union Against Tuberculosis and Lung Disease, Paris, France
    JAMA 305:1415-23. 2011
  3. ncbi What research is needed to stop TB? Introducing the TB Research Movement
    Christian Lienhardt
    Stop TB Partnership, World Health Organization, Geneva, Switzerland
    PLoS Med 8:e1001135. 2011
  4. ncbi New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future
    Christian Lienhardt
    Stop TB Partnership and Stop TB Department, World Health Organisation, 20 Ave Appia, CH 1211, Geneva 27, Switzerland
    J Infect Dis 205:S241-9. 2012
  5. ncbi The blueprint for vaccine research & development: walking the path for better TB vaccines
    Christian Lienhardt
    Stop TB Partnership, World Health Organization, Geneva, Switzerland
    Tuberculosis (Edinb) 92:S33-5. 2012
  6. ncbi Evaluation of the prognostic value of IFN-gamma release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal
    Christian Lienhardt
    Institut de Recherche pour le Developpement, Programme Tuberculose, Dakar, Senegal
    PLoS ONE 5:e10508. 2010
  7. ncbi Operational research for improved tuberculosis control: the scope, the needs and the way forward
    C Lienhardt
    Stop TB Partnership and Stop TB Department, World Health Organization, Geneva, Switzerland
    Int J Tuberc Lung Dis 15:6-13. 2011
  8. ncbi Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities
    C Lienhardt
    Stop TB Partnership and Stop TB Department, World Health Organization, Geneva, Switzerland
    Int J Tuberc Lung Dis 14:528-37. 2010
  9. ncbi Scaling up interventions to achieve global tuberculosis control: progress and new developments
    Mario Raviglione
    Stop TB Department, WHO, Geneva, Switzerland
    Lancet 379:1902-13. 2012
  10. ncbi Global tuberculosis control: lessons learnt and future prospects
    Christian Lienhardt
    Stop TB Department, World Health Organization, Desk D4 6017, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Nat Rev Microbiol 10:407-16. 2012

Collaborators

Detail Information

Publications18

  1. ncbi New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes
    Christian Lienhardt
    Stop TB Department and Stop TB Partnership, World Health Organization, Geneva, Switzerland
    Curr Opin Pulm Med 16:186-93. 2010
    ....
  2. ncbi Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial
    Christian Lienhardt
    Clinical Trial Division, International Union Against Tuberculosis and Lung Disease, Paris, France
    JAMA 305:1415-23. 2011
    ..Fixed-dose combinations (FDCs) of drugs for treatment of tuberculosis have been advocated to prevent the emergence of drug resistance...
  3. ncbi What research is needed to stop TB? Introducing the TB Research Movement
    Christian Lienhardt
    Stop TB Partnership, World Health Organization, Geneva, Switzerland
    PLoS Med 8:e1001135. 2011
  4. ncbi New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future
    Christian Lienhardt
    Stop TB Partnership and Stop TB Department, World Health Organisation, 20 Ave Appia, CH 1211, Geneva 27, Switzerland
    J Infect Dis 205:S241-9. 2012
    ....
  5. ncbi The blueprint for vaccine research & development: walking the path for better TB vaccines
    Christian Lienhardt
    Stop TB Partnership, World Health Organization, Geneva, Switzerland
    Tuberculosis (Edinb) 92:S33-5. 2012
    ....
  6. ncbi Evaluation of the prognostic value of IFN-gamma release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal
    Christian Lienhardt
    Institut de Recherche pour le Developpement, Programme Tuberculose, Dakar, Senegal
    PLoS ONE 5:e10508. 2010
    ..To address this, we investigated the response to TST and IGRA in household contacts of infectious TB cases in a TB high-burden country and the potential correlation with development of TB...
  7. ncbi Operational research for improved tuberculosis control: the scope, the needs and the way forward
    C Lienhardt
    Stop TB Partnership and Stop TB Department, World Health Organization, Geneva, Switzerland
    Int J Tuberc Lung Dis 15:6-13. 2011
    ..Suggestions are made for potential steps for improved purpose-driven OR, which may help to improve TB control locally and inform policy recommendations internationally...
  8. ncbi Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities
    C Lienhardt
    Stop TB Partnership and Stop TB Department, World Health Organization, Geneva, Switzerland
    Int J Tuberc Lung Dis 14:528-37. 2010
    ..As with HIV, clinical trials in patients with drug-resistant disease may provide a quicker and less expensive path to licensure than trials for treatment of drug-susceptible disease...
  9. ncbi Scaling up interventions to achieve global tuberculosis control: progress and new developments
    Mario Raviglione
    Stop TB Department, WHO, Geneva, Switzerland
    Lancet 379:1902-13. 2012
    ..International and national financial uncertainty places gains at serious risk. Perseverance and renewed commitment are needed to achieve global control of tuberculosis, and ultimately, its elimination...
  10. ncbi Global tuberculosis control: lessons learnt and future prospects
    Christian Lienhardt
    Stop TB Department, World Health Organization, Desk D4 6017, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Nat Rev Microbiol 10:407-16. 2012
    ....
  11. ncbi Improving tuberculosis control: an interdisciplinary approach
    Christian Lienhardt
    , Programme Tuberculose, UMR 145 Montpellier, France
    Lancet 367:949-50. 2006
  12. ncbi Cochrane systematic review of directly observed therapy for treating tuberculosis: good analysis of the wrong outcome
    I D Rusen
    International Union Against Tuberculosis and Lung Disease, Paris, France
    Int J Tuberc Lung Dis 11:120-1. 2007
  13. ncbi Sensitivity of IFN-gamma release assay to detect latent tuberculosis infection is retained in HIV-infected patients but dependent on HIV/AIDS progression
    Farba Karam
    Laboratoire de Bacteriologie virologie, Hopital Aristide Le Dantec, Dakar, Senegal
    PLoS ONE 3:e1441. 2008
    ..Detection and treatment of latent TB infection (LTBI) in HIV infected individuals is strongly recommended to decrease morbidity and mortality in countries with high levels of HIV...
  14. ncbi Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial
    Sylla Thiam
    Institut de Recherche pour le Developpement, Programme Tuberculose, Dakar, Senegal
    JAMA 297:380-6. 2007
    ..Poor adherence to treatment remains a major obstacle to efficient tuberculosis (TB) control in developing countries. Innovative strategies to improve access and adherence to treatment are needed...
  15. ncbi Improving the prevention, diagnosis and treatment of TB among people living with HIV: the role of operational research
    Delphine Sculier
    Stop TB Department, World Health Organization, 20 Avenue Appia, 1211 Geneva, Switzerland
    J Int AIDS Soc 14:S5. 2011
    ....
  16. ncbi Risk factors for tuberculosis infection in sub-Saharan Africa: a contact study in The Gambia
    Christian Lienhardt
    IRD, BP 1386, Dakar, Senegal
    Am J Respir Crit Care Med 168:448-55. 2003
    ....
  17. ncbi Tuberculosis control in resource-poor countries: have we reached the limits of the universal paradigm?
    Christian Lienhardt
    Institut de Recherche pour le Developpement, Dakar, Senegal
    Trop Med Int Health 9:833-41. 2004
    ..This analysis is of particular importance as programmers consider using this model in the delivery of anti-retroviral therapies for the treatment of HIV in resource-limited settings...
  18. ncbi Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues
    N Ait-Khaled
    International Union Against Tuberculosis and Lung Disease, Paris, France
    Int J Tuberc Lung Dis 13:927-35. 2009
    ..There is a definite risk that 'sloppy' IPT will be inefficient and, worse, could lead to the development of multidrug-resistant TB, and this must be avoided at all costs...